Voloridge Investment Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-100,315
Closed -$6.54M 1483
2022
Q2
$6.54M Sell
100,315
-82,170
-45% -$4.86M 0.03% 578
2022
Q1
$11.5M Buy
182,485
+119,056
+188% +$6.47M 0.07% 380
2021
Q4
$3.36M Sell
63,429
-49,501
-44% -$3.02M 0.02% 873
2021
Q3
$7.97M Sell
112,930
-94,090
-45% -$5.94M 0.05% 506
2021
Q2
$13.8M Buy
207,020
+171,861
+489% +$12.2M 0.1% 284
2021
Q1
$3.9M Buy
+35,159
New +$4.35M 0.03% 603
2020
Q4
Sell
-67,585
Closed -$5.9M 1417
2020
Q3
$5.9M Sell
67,585
-29,572
-30% -$2.58M 0.05% 404
2020
Q2
$8.7M Buy
+97,157
New +$9.81M 0.1% 231
2020
Q1
Sell
-24,403
Closed -$2.8M 1211
2019
Q4
$2.8M Buy
24,403
+2,115
+9% +$256K 0.05% 410
2019
Q3
$2.81M Buy
+22,288
New +$2.83M 0.05% 367
2019
Q2
Sell
-24,683
Closed -$2.16M 878
2019
Q1
$2.16M Buy
+24,683
New +$2.24M 0.07% 275
2018
Q3
Sell
-26,855
Closed -$2.41M 365
2018
Q2
$2.41M Buy
+26,855
New +$2.27M 0.06% 257
2018
Q1
Sell
-17,608
Closed -$1.02M 551
2017
Q4
$1.02M Buy
+17,608
New +$927K 0.02% 373

Other funds holding HAE

Voloridge Investment Management's HAE Position: Q3 2022 in Review

Voloridge Investment Management sold out of Haemonetics (HAE) in Q3 2022, closing a stake of 100,315 shares — an estimated $6.54M sold.

Voloridge Investment Management first reported a position in HAE in Q4 2017 and held it in 13 quarters. The position peaked at $13.8M in Q2 2021. 270 funds tracked by Wall St. Rank hold HAE as of Q3 2022.

  • Voloridge Investment Management reported no remaining Haemonetics position as of Q3 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 100,315 Haemonetics shares in Q3 2022, an estimated $6.54M.
  • Voloridge Investment Management first reported a position in Haemonetics in Q4 2017 and held it in 13 quarters.
  • Voloridge Investment Management's Haemonetics position peaked at $13.8M in Q2 2021.
  • 270 funds tracked by Wall St. Rank held Haemonetics as of Q3 2022.

Based on Voloridge Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.